The Association between Chlamydia infection and Extrahepatic Biliary Atresia, a case control study

The Association between Chlamydia infection and Extrahepatic Biliary Atresia, a case control study - BACHERA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38798

Enrollment

Registered

2013-10-16

Start date

2013-11-07

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bile duct atresia vanishing bile ducts

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Biopsy proven biliary atresia * Underwent Kasai operation * Liver tissue stored at the department of pathology * Outpatient follow up in the Academic Medical Center, Amsterdam or University Medical Centre Groningen * Younger then 12 years * Informed consent of custodial parent(s) or guardian, for inclusion of their child * Informed consent of the mother for the withdrawal of maternal blood for ELISA on Chlamydia

Exclusion criteria

Exclusion criteria: * Patients with embryonic biliary atresia * Older then 12 years

Design outcomes

Primary

Measure	Time frame
The presence of Chlamydia IgA antibody in serum of Dutch patients with biliary atresia, compared to the control group. The presence of Chlamydia in liver tissue (liver biopsy and fibrotic remnant obtained during Kasai operation) of BA patients as compared to controls, examined by PCR as well as Chlamydia-specific staining by immunohistochemistry. In case indications for DNA abnormalities will arise, the remainder of the serum will be used for DNA analysis.	—

Measure

Time frame

The presence of Chlamydia IgA antibody in serum of Dutch patients with biliary atresia, compared to the control group. The presence of Chlamydia in liver tissue (liver biopsy and fibrotic remnant obtained during Kasai operation) of BA patients as compared to controls, examined by PCR as well as Chlamydia-specific staining by immunohistochemistry. In case indications for DNA abnormalities will arise, the remainder of the serum will be used for DNA analysis.

—

Secondary

Measure	Time frame
The presence of Chlamydia IgA antibody in serum of mothers of patients with biliary atresia, compared to the presence of Chlamydia IgA antibody in serum of mothers of the control group and the presence of Chlamydia IgA antibody in the general population.	—

Countries

Netherlands

Outcome results